There appears to be a malediction attached to the €20 share price for Glanbia. After four years hovering under that threshold, the stock of the Kilkenny-headquartered nutrition multinational experienced its first collapse in 2019 when it became clear that its chase for growth had left it with inefficient, bloated structures. A patient restructuring programme under cover of the pandemic restored confidence among investors and Glanbia shares were again trading over €19 last June. Yet, after chief executive Hugh McGuire lowered its 2025 performance outlook when delivering annual results on Wednesday, the stock is again in the same €11 doldrums it…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €50.

Subscribe

Cancel at any time.

Are you already a member? .